Novavax Inc (NVAX) stock
NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$8.53−0.23 (-2.68%)
Close on Nov 13, 2026Market cap $1.41BP/E –Yield –
Novavax profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Novavax's profit margin for the twelve months ending Sep 30, 2026 was -18.6%. For fiscal 2025 it was 39.2%, against -27.5% the year before. The highest annual figure on record is 39.2% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 39.2% | +66.7 |
| FY2024 | Dec 31, 2024 | -27.5% | +27.9 |
| FY2023 | Dec 31, 2023 | -55.4% | −22.2 |
| FY2022 | Dec 31, 2022 | -33.2% | +118.9 |
| FY2021 | Dec 31, 2021 | -152.1% | −64.2 |
| FY2020 | Dec 31, 2020 | -87.9% | +623.1 |
| FY2019 | Dec 31, 2019 | -711.0% | −172.2 |
| FY2018 | Dec 31, 2018 | -538.8% | +50.6 |
| FY2017 | Dec 31, 2017 | -589.5% | +1234.1 |
| FY2016 | Dec 31, 2016 | -1823.5% | −1390.6 |
| FY2015 | Dec 31, 2015 | -432.9% | −162.4 |
| FY2014 | Dec 31, 2014 | -270.5% | −22.0 |
| FY2013 | Dec 31, 2013 | -248.5% | −119.4 |
| FY2012 | Dec 31, 2012 | -129.1% | +2.7 |
| FY2011 | Dec 31, 2011 | -131.8% | +10278.7 |
| FY2010 | Dec 31, 2010 | -10410.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -45.9% | +241.3 |
| Q2 FY2026 | Jun 30, 2026 | -94.2% | −138.7 |
| Q1 FY2026 | Mar 31, 2026 | -6.8% | −84.6 |
| Q4 FY2025 | Dec 31, 2025 | 11.9% | +103.7 |
| Q3 FY2025 | Sep 30, 2025 | -287.3% | −143.8 |
| Q2 FY2025 | Jun 30, 2025 | 44.5% | +5.4 |
| Q1 FY2025 | Mar 31, 2025 | 77.8% | +235.0 |
| Q4 FY2024 | Dec 31, 2024 | -91.8% | −30.5 |
| Q3 FY2024 | Sep 30, 2024 | -143.5% | −73.6 |
| Q2 FY2024 | Jun 30, 2024 | 39.1% | +25.4 |
| Q1 FY2024 | Mar 31, 2024 | -157.2% | +205.9 |
| Q4 FY2023 | Dec 31, 2023 | -61.2% | −10.2 |
| Q3 FY2023 | Sep 30, 2023 | -69.9% | −47.0 |
| Q2 FY2023 | Jun 30, 2023 | 13.7% | +288.2 |
| Q1 FY2023 | Mar 31, 2023 | -363.1% | −392.0 |
| Q4 FY2022 | Dec 31, 2022 | -51.0% | +329.9 |
| Q3 FY2022 | Sep 30, 2022 | -23.0% | +157.3 |
| Q2 FY2022 | Jun 30, 2022 | -274.6% | −156.3 |
| Q1 FY2022 | Mar 31, 2022 | 28.9% | +78.7 |
| Q4 FY2021 | Dec 31, 2021 | -380.9% | −317.4 |
| Q3 FY2021 | Sep 30, 2021 | -180.3% | −54.6 |
| Q2 FY2021 | Jun 30, 2021 | -118.2% | −68.9 |
| Q1 FY2021 | Mar 31, 2021 | -49.8% | +716.1 |
| Q4 FY2020 | Dec 31, 2020 | -63.5% | +297.6 |
| Q3 FY2020 | Sep 30, 2020 | -125.7% | +594.0 |
| Q2 FY2020 | Jun 30, 2020 | -49.3% | +1130.4 |
| Q1 FY2020 | Mar 31, 2020 | -765.9% | +319.4 |
| Q4 FY2019 | Dec 31, 2019 | -361.0% | +444.1 |
| Q3 FY2019 | Sep 30, 2019 | -719.7% | −143.5 |
| Q2 FY2019 | Jun 30, 2019 | -1179.7% | −766.7 |
| Q1 FY2019 | Mar 31, 2019 | -1085.3% | −605.2 |
| Q4 FY2018 | Dec 31, 2018 | -805.2% | −316.9 |
| Q3 FY2018 | Sep 30, 2018 | -576.2% | −42.1 |
| Q2 FY2018 | Jun 30, 2018 | -413.0% | +247.5 |
| Q1 FY2018 | Mar 31, 2018 | -480.2% | +291.9 |
| Q4 FY2017 | Dec 31, 2017 | -488.3% | +569.5 |
| Q3 FY2017 | Sep 30, 2017 | -534.1% | – |
| Q2 FY2017 | Jun 30, 2017 | -660.5% | – |
| Q1 FY2017 | Mar 31, 2017 | -772.1% | – |
| Q4 FY2016 | Dec 31, 2016 | -1057.8% | – |
See a number that looks wrong?